Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 43

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
 124,650  
     72,020  
     52,630 
  
    Total sales, net 
    $6,916,003  
    $6,616,414  
    $299,589 

Consolidated revenue for the nine months ended September 30, 2025, was
approximately $6.9 million, compared to $6.6 million for the same period in 2024, representing an increase of approximately $300,000,
or 5%. The year-over-year improvement was primarily driven by higher international and medical sales, partially offset by declines in
e-commerce and institutional dental revenue.

Revenue from Dental Service Organizations (DSOs), government agencies,
and dental schools totaled approximately $277,000 for the nine months ended September 30, 2025, compared to $316,000 in the prior-year
period, reflecting a decrease of approximately $39,000, or 12%.

E-commerce dental revenue decreased to approximately $3.3 million for the
nine months ended September 30, 2025, from $3.5 million for the same period in 2024, a decline of approximately $239,000, or 7%. The reduction
was primarily attributable to lower order volumes and timing differences in recurring purchases from certain online distributors.

International revenue for the nine months ended
September 30, 2025, was approximately $2.9 million compared to $2.7 million for the
same period in 2024, an increase of approximately $211,000, or 8%.

Sales
in China for the nine months ended September 30, 2025, were approximately $310,000, compared to no sales in the same period of 2024.
The increase reflects the Company’s successful efforts to reestablish operations and distribution channels in the region following
prior-year market disruptions.

Medical revenue also increased, totaling approximately $125,000 for the
nine months ended September 30, 2025, compared to $74,000 in the prior-year period, representing an increase of approximately $51,000,
or 69%. The increase primarily reflects ongoing progress in expanding the clinical use and adoption of the CompuFlo® Epidural and
CathCheck® Systems within the pain management and anesthesia markets.

Gross
Profit for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental